Le Lézard
Classified in: Health
Subject: MISCELLANEOUS

Breast Cancer Canada announces $500K in new grant funding


SARNIA, Ontario, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Breast Cancer Canada today announced a call for proposals for their 2023 Precision Oncology Research Grants which will award $500,000 in new funding for breast cancer research projects. The submission period begins today, December 1, and will remain open until December 23, 2022.

Thanks to the generous support of Breast Cancer Canada donors through 2022, the organization has increased their new grants funding for the year ahead by $150,000 for their second annual call for proposals. The organization granted $350,000 in new funding to precision oncology projects across Canada in 2022, many of which are continuing into the new year.

"With several Canadian organizations having to reduce funding for breast cancer research, we are proud to continue elevating precision oncology research projects that will have direct impact on patients," said Shaniah Leduc, Chair of Breast Cancer Canada. "We know because of research there are more than 50 types of breast cancer. Precision oncology research allows us to more accurately diagnose breast cancer and design treatment plans targeted to the patient's specific type of breast cancer. The goal is to match the right treatment, to the right person, at the right time."

Breast Cancer Canada's Scientific Advisory Committee is leading the selection process and is committed to listening to breast cancer patients. All funded project teams are required to include a breast cancer patient advocate or a local breast cancer advocacy group as part of their research. 

The selected projects will focus on precision oncology that deliver individualized treatment models and accelerate the transition from standard approaches for breast cancer treatment, to the new age of personalized medicine. The projects will surround four divisions of precision oncology research: basic science, screening and detection, personalized treatment, and patient reported outcomes. All projects must also include an artificial intelligence (AI) component.

"We are incredibly grateful to our donors, partners and volunteers for the unwavering support throughout 2022. As our donations increase, so does the number of projects we can fund. Together, we are saving lives through breast cancer research" said Kimberly Carson, CEO, Breast Cancer Canada."

Canadian scientists and researchers are invited to submit an application for precision oncology breast cancer research projects by December 23, 2022. For more information and to apply, please visit breastcancerprogress.ca.  

Breast Cancer Canada
Breast Cancer Canada (BCC) is a national, registered charity dedicated to saving lives through breast cancer research. BCC raises money to fund patient-focused research for the diagnosis and treatment of breast cancer. For more information, please visit breastcancerprogress.ca

MEDIA CONTACTS

Victoria Mahoney, Harmony Marketing
416-464-7606
[email protected]

Angela Marlatt, Breast Cancer Canada
800-567-8767 ext. 707
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/20b46eaa-215a-49d3-b3ad-46206b4dc889



These press releases may also interest you

at 09:15
Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today shared an update on its strategic partnerships with leading experts in data science, sensor technology, product design and regulatory affairs. These...

at 09:15
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced plans for presenting...

at 09:10
PharmaCyte Biotech, Inc. ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of cellular therapies for cancer, diabetes and...

at 09:10
LivaNova PLC , a market-leading medical technology and innovation company, today launched SenTiva DUOtm, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapytm for the treatment of drug-resistant epilepsy. The dual-pin...

at 09:10
AstraZeneca and Amgen's TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma...

at 09:09
Platform Life Sciences, a high impact Clinical Research Organization, with the mission to modernize clinical trials on a global scale, has signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a...



News published on 1 december 2022 at 14:00 and distributed by: